[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356617-105":59,"doc-detail-356617-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","proteogenomic-decoding-of-chemotherapy-resistance-in-patients-with-triple-negative-breast-cancer","Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer","","Integrated proteogenomic biomarkers to forecast chemotherapy response in triple-negative breast cancer remain insufficiently understood. This study prospectively analyzed paired baseline and post-treatment tumor samples from 50 stage II–III TNBC patients receiving anthracycline- and taxane-based neoadjuvant chemotherapy. Whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics enabled proteogenomic subtype stratification and pathway-specific signals. The approach reveals immune-enriched features linked to high pathologic complete response, estrogen-linked mechanisms associated with resistance, residual-disease AURKB activation, and a biomarker model outperforming RNA-only prediction.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/proteogenomic-decoding-of-chemotherapy-resistance-in-patients-with-triple-negative-breast-cancer/356617/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/proteogenomic-decoding-of-chemotherapy-resistance-in-patients-with-triple-negative-breast-cancer/356617.png","ImageObject",300,407,{"name":92,"@type":93},"Sophia Brooks","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were proteogenomic biomarkers evaluated in this study?","Question",{"text":112,"@type":113},"The study analyzed paired baseline and post-treatment tumor samples using whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics from 50 stage II–III TNBC patients treated with anthracycline- and taxane-based neoadjuvant chemotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What proteogenomic subtypes were identified and how did they relate to response?",{"text":117,"@type":113},"Non-negative matrix factorization clustering identified five proteogenomic subtypes. The immune-enriched subtype showed the highest pathologic complete response rate, while xenobiotic metabolism and epithelial–mesenchymal transition subtypes showed no pathologic complete response.",{"name":119,"@type":110,"acceptedAnswer":120},"Which mechanisms and targets were linked to chemotherapy resistance and residual disease?",{"text":121,"@type":113},"The study reports estrogen-linked GRK2 activation contributing to chemotherapy resistance. It also finds AURKB pathway activation in residual disease and that Aurora B kinase inhibition can synergize with paclitaxel, supporting actionable therapeutic implications.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},356617,1790155830,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Lee et al. Genome Biology (2026) 27:125 [https://doi.org/10.1186/s13059-026-04053-7](https://doi.org/10.1186/s13059-026-04053-7)  \nGenome Biology  \nRESEARCH Open Access  \nProteogenomic decoding of chemotherapy   resistance in patients with triple-negative breast cancer  \nDong Ki Lee1,2†, Min Hwan Kim2†, Yumi Hwang3, Seul-Gi Kim4, Won-Ji Ryu3, Geon-Uk Kim3, Hyun Myoung Yun3, Shinyoung Park3, Jeong Dong Lee3, Hyun Ju Han3, Gun Min Kim2, Kyung-Hee Kim5, Jong Bae Park6, Min Jung Kim7, Ja Seung Koo8, Jee Ye Kim9, Hyung Seok Park9, Seung Il Kim9, Heon Yung Gee1,  \nSeho Park9*† and Joohyuk Sohn2*†  \n\n| †Dong Ki Lee and Min Hwan Kim contributed equally to this work. |\n| --- |\n| †Seho Park and Joohyuk Sohn jointly supervised this work. |\n| *Correspondence:\u003Cbr>[psh1025@yuhs.ac](psh1025@yuhs.ac);\u003Cbr>[oncosohn@yuhs.ac](oncosohn@yuhs.ac) |\n\n2 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea  \n9 Division of Breast Surgery, Department of Surgery, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea Full list of author information is available at the end of the article  \nAbstract  \nBackground: The clinical utility of integrated proteogenomic biomarkers for predicting chemotherapy response in triple-negative breast cancer remains underexplored. We prospectively analyzed paired baseline and post-treatment tumor samples from 50 patients with stage II–IIITNBC treated with anthracycline-and taxane-based neoadjuvant chemotherapy, integrating whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics.  \nResults: Non-negative matrix factorization clustering identifies five proteogenomic subtypes. The immune-enriched subtype demonstrates the highest pathologic complete response rate (55 . 6%), whereas no pathologic complete response was observed in the xenobiotic metabolism or epithelial–mesenchymal transition subtypes.  \nImmune-related pathways are enriched in tumors with pathologic complete response, while epithelial–mesenchymal transition pathways are enriched in non-pathologic complete response tumors. The estrogen response pathway is selectively enriched in non-pathologic complete response tumors at the proteomic level and inversely correlated with immune activation. Post-translational modification and in vitro analyses suggest estrogen-linked GRK2 activation contributes to chemotherapy resistance. ITGB8 copy number loss is associated with higher pathologic complete response ratesand immune activation, while non-pathologic complete response tumors ofthe immunomodulatory subtype show increased expression of AKR1C2 andABCA13 . Comparison of baseline and post-treatment tumors reveals AURKB pathway activation in residual disease, with Aurora B kinase inhibition synergizing with paclitaxel. A predictive model incorporating these biomarkers outperforms RNA-based models in predicting response.  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holde","cbCainsXoTdPn46L","https://ap.wps.com/l/cbCainsXoTdPn46L","pdf",4307251,25,"English","# Abstract\n## Background\n## Results\n## Conclusion\n# Background","[{\"question\":\"How were proteogenomic biomarkers evaluated in this study?\",\"answer\":\"The study analyzed paired baseline and post-treatment tumor samples using whole-exome sequencing, RNA sequencing, global proteomics, and phosphoproteomics from 50 stage II–III TNBC patients treated with anthracycline- and taxane-based neoadjuvant chemotherapy.\"},{\"question\":\"What proteogenomic subtypes were identified and how did they relate to response?\",\"answer\":\"Non-negative matrix factorization clustering identified five proteogenomic subtypes. The immune-enriched subtype showed the highest pathologic complete response rate, while xenobiotic metabolism and epithelial–mesenchymal transition subtypes showed no pathologic complete response.\"},{\"question\":\"Which mechanisms and targets were linked to chemotherapy resistance and residual disease?\",\"answer\":\"The study reports estrogen-linked GRK2 activation contributing to chemotherapy resistance. It also finds AURKB pathway activation in residual disease and that Aurora B kinase inhibition can synergize with paclitaxel, supporting actionable therapeutic implications.\"}]","Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer | PDF",1790126323,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27aeac9b33c4ddf95cd3cfb8190e0b7c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd711f6cca87dfef6b1b3df37f711c18.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c058a1e499a92b0cc690bb82ed075b77.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/31968edf311db181fe75278da4d170a6.webp",980,1301]